Delcath Systems, Inc. (DCTH)
Nasdaq · Healthcare · Medical Devices
$15.87+4.89%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $551M
- P/E (trailing)
- 1587.0
- Forward P/E
- 352.7
- 52-week range
- $8.12 – $17.42
- 52-week change
- +40.09%
- EPS (trailing)
- $0.01
- Next earnings
- Nov 3, 2026
Fiscal year to Dec 2025
- Revenue
- $85.2M (+129.08%)
- Net income
- $2.7M
- Operating margin
- 0.8%
- Diluted EPS
- $0.07
- Free cash flow
- $21.0M
From the company’s annual report on SEC EDGAR.
About Delcath Systems, Inc.
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.
Headquarters: Queensbury, United States · 156 employees · delcath.com